Depressed activation of the lectin pathway of complement in hereditary angioedema
13rd Department of Internal Medicine, Semmelweis University, Hungarian Academy of Sciences, Budapest, Hungary. lvarga@kut.sote.hu
Insights
This study shows that the lectin pathway (LP) of complement activation may occur in hereditary angioedema (HAE) patients with C1-inhibitor (C1INH) deficiency, indicated by lower MASP-2 and C4 levels. This finding offers new insights into complement system dysregulation in HAE.
Area of Science:
- Immunology
- Complement System Biology
- Genetic Disorders
Background:
- Hereditary angioedema (HAE) is characterized by C1-inhibitor (C1INH) deficiency and complement system dysregulation.
- The Wielisa method enables simultaneous measurement of classical pathway (CP), mannan-binding lectin (MBL)-lectin pathway (LP), and alternative pathway (AP) complement activation.
- Understanding the in vivo role of C1INH across all three complement pathways is crucial for HAE research.
Purpose of the Study:
- To investigate the in vivo significance of C1-inhibitor (C1INH) in the CP, LP, and AP of complement activation.
- To compare complement pathway activities and associated protein levels in HAE patients versus healthy controls.
- To explore the relationship between MBL-2 genotypes and LP activity in HAE patients.
Main Methods:
- Simultaneous measurement of CP, LP, and AP functional activity using the Wielisa method in 68 HAE patients and 64 healthy controls.
- Quantification of C1q, MBL, MASP-2, C4, C3, and C1INH levels using standard laboratory assays.
- Determination of MBL-2 genotypes via polymerase chain reaction.
Main Results:
- HAE patients exhibited lower CP and C1INH activity, and reduced C4 and C1INH concentrations compared to controls.
- MASP-2 levels were significantly lower in HAE patients (P = 0.0001).
- Depressed LP activity was observed in HAE patients with the normal MBL genotype (A/A) (P = 0.0008), but not in those with variant genotypes.
- CP and LP activity correlated in HAE patients (r = 0.64; P < 0.0001), while CP and AP correlated in controls (r = 0.47; P < 0.0001).
Conclusions:
- The lectin pathway (LP) may be activated in individuals with C1INH deficiency, as suggested by low MASP-2 and C4 levels.
- Complement pathway interactions differ between HAE patients and healthy individuals.
- These findings highlight potential LP involvement in the pathophysiology of HAE.
Abstract:
The possibility of simultaneous measurement of the classical pathway (CP), mannan-binding lectin (MBL)--lectin pathway (LP) and alternative pathway (AP) of complement activation by the recently developed Wielisa method allowed us to investigate the in vivo significance of the C1-inhibitor (C1INH) in three complement activation pathways. Functional activity of the CP, LP and AP were measured in the sera of 68 adult patients with hereditary angioedema (HAE) and 64 healthy controls. In addition, the level of C1q, MBL, MBL-associated serine protease-2 (MASP-2), C4-, C3- and C1INH was measured by standard laboratory methods. MBL-2 genotypes were determined by polymerase chain reaction. Besides the complement alterations (low CP and C1INH activity, low C4-, C1INH concentrations), which characterize HAE, the level of MASP-2 was also lower (P = 0.0001) in patients compared with controls. Depressed LP activity was found in patients compared with controls (P = 0.0008) in homozygous carriers of the normal MBL genotype (A/A), but not in carriers of variant genotypes (A/O, O/O). Activity of CP correlated with LP in patients (Spearman's r = 0.64; P < 0.0001), but no significant correlation was found in the control group and no correlation with AP was observed. In contrast, the activity of CP and AP correlated (Spearman's r = 0.47; P < 0.0001) in healthy controls, but there was no significant correlation in the HAE patients. We conclude that the activation of LP might also occur in subjects with C1INH deficiency, which is reflected by the low MASP-2 and C4 levels.
Related Concept Videos
Complement System
Cytotoxic Edema: Pathophysiology
Selectins
Cerebral Edema ll: Pathophysiology
Lysosomal Hydrolases
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

